Compare MKTW & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MKTW | LGVN |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.7M | 34.0M |
| IPO Year | 2020 | 2021 |
| Metric | MKTW | LGVN |
|---|---|---|
| Price | $17.65 | $0.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $20.00 | $3.00 |
| AVG Volume (30 Days) | 24.9K | ★ 814.5K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 10.33% | N/A |
| EPS Growth | ★ 1183.33 | 50.76 |
| EPS | ★ 2.31 | N/A |
| Revenue | ★ $512,403,000.00 | $709,000.00 |
| Revenue This Year | $1.52 | N/A |
| Revenue Next Year | $4.55 | $10.81 |
| P/E Ratio | $7.56 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.65 | $0.48 |
| 52 Week High | $21.74 | $1.80 |
| Indicator | MKTW | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 55.90 | 38.96 |
| Support Level | $16.06 | $0.74 |
| Resistance Level | $20.62 | $0.99 |
| Average True Range (ATR) | 0.87 | 0.07 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 77.84 | 0.63 |
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms, including mobile, desktop, and tablets.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.